RIFATER
LOE ApproachingNDAORALTABLET
Approved
May 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 56m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIFATER is an oral tablet small-molecule combination product approved by Sanofi in 1994. The specific indications and mechanism of action are not publicly detailed in available data, limiting characterization of therapeutic scope. This is a legacy NDA product with well-established market presence.
LOE Approaching
Product is approaching loss of exclusivity with low competitive pressure (30/100), signaling potential team consolidation and transition focus away from growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, career opportunities on RIFATER are limited and defensive in nature. Professionals joining this product should expect focus on cost management, generic defense, and margin optimization rather than market expansion.
Brand ManagerProduct Manager
Worked on RIFATER at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.